The Eight New Cancer Treatments that Received FDA Approval in 2013

Healthcare Training Resource
March 18, 2014 — 1,550 views  
Become a Bronze Member for monthly eNewsletter, articles, and white papers.

In 2013, the FDA approved over a dozen treatments for cancer, with sorafenib (Nexavar) being the latest drug approved. The drug was approved for treating differentiated thyroid carcinoma or DTC in the late stages in November last year. The drug limits the growth of cancer cells and is aimed at patients with late stage thyroid cancer that has not responded to the radioactive iodine approach.

Another drug approved was crizotinib for patients with lung cancer. The dose that is recommended of the drug is 250 mg, two times a day. This drug can be administered orally.

Ibrutinib was also granted approval by the FDA last year for the treatment of patients suffering from mantle cell lymphoma or MCL, along with patients who have been given at least one prior therapy session. The dose of ibrutinib is 560 mg, administered orally once a day. The approval was given on the basis of an international single-arm trial.

Combination cancer drugs

Obinutuzumab was also given FDA approval for use in treatment along with chlorambucil among patients with chronic lymphocytic leukemia, not treated earlier. The treatment, however, comes with a warning in connection with Hepatitis B virus, which could be reactivated. Healthcare professionals should warn patients of the risks of the virus being re-activated.

For patients with early stage breast cancer, the FDA approved the pertuzumab injection to be used along with trastuzumab and doscetaxel. There is not enough evidence to suggest the use of pertuzumab for over six cycles for breast cancer in the early cycles, though.

For patients suffering from late stage adenocarcinoma of the pancreas, the FDA approved paclitaxel protein-bound particles for use along with gemcitabine. The use of this treatment can slow down growth in some tumors.

Afatinib and denosumab

Two other cancer drugs that were approved by the FDA last year, among others, were afatinib, which can be used for those with late stage non small cell lung cancer, and denosumab for those with giant cell bone tumor that cannot come under resection through surgery. Afatinib is for patients with tumors that have gene mutations making cells grow rapidly. The mutations are detected by way of a test which also received FDA approval. Denosumab is among the cancer drugs that were FDA approved last year, and is for treatment among patients who are adolescents with mature skeletal systems or adults. The drug is actually used to check factures or bone troubles that can happen since cancer can be detrimental to the bones.

Healthcare Training Resource